SI0779810T1 - Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes - Google Patents

Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Info

Publication number
SI0779810T1
SI0779810T1 SI9430454T SI9430454T SI0779810T1 SI 0779810 T1 SI0779810 T1 SI 0779810T1 SI 9430454 T SI9430454 T SI 9430454T SI 9430454 T SI9430454 T SI 9430454T SI 0779810 T1 SI0779810 T1 SI 0779810T1
Authority
SI
Slovenia
Prior art keywords
ketoconazole
diabetes
medicaments
type
treatment
Prior art date
Application number
SI9430454T
Other languages
English (en)
Slovenian (sl)
Inventor
Per Marin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Publication of SI0779810T1 publication Critical patent/SI0779810T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • B65B1/08—Methods of, or means for, filling the material into the containers or receptacles by vibratory feeders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9430454T 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes SI0779810T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1994/000729 WO1996004912A1 (en) 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Publications (1)

Publication Number Publication Date
SI0779810T1 true SI0779810T1 (en) 2003-12-31

Family

ID=20393155

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9430454T SI0779810T1 (en) 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Country Status (14)

Country Link
US (2) US5849740A (cs)
EP (2) EP0779810B8 (cs)
JP (1) JP3825469B2 (cs)
KR (1) KR100422162B1 (cs)
AT (1) ATE244009T1 (cs)
CA (1) CA2196174C (cs)
CZ (1) CZ285290B6 (cs)
DE (1) DE69432905T2 (cs)
DK (1) DK0779810T3 (cs)
ES (1) ES2202326T3 (cs)
NO (1) NO314616B1 (cs)
PT (1) PT779810E (cs)
SI (1) SI0779810T1 (cs)
WO (1) WO1996004912A1 (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT779810E (pt) * 1994-08-09 2003-11-28 Cortendo Ab Utilizacao de cetoconazole e substancias relacionadas em medicamentos para o tratamento da diabetes tipo ii
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
WO2003055975A2 (en) * 2001-08-23 2003-07-10 New England Biolabs, Inc. A method for engineering strand-specific, sequence-specific, dna-nicking enzymes
ES2346961T3 (es) 2001-11-22 2010-10-22 Biovitrum Ab Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
EP2053409A1 (en) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Specific markers for metabolic syndrome
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
KR101387910B1 (ko) 2005-01-10 2014-04-25 콜텐도 인베스트 아베 당뇨병, 대사 증후군 및 다른 질환을 치료하기 위한 방법및 조성물
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
JP2006206605A (ja) * 2006-03-29 2006-08-10 Metabolic Syndrome I Goeteborg Ab 代謝性症候群の治療薬
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
NZ576569A (en) * 2006-10-02 2012-05-25 Cortendo Ab Publ Ketoconazole enantiomer in humans
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
PT779810E (pt) * 1994-08-09 2003-11-28 Cortendo Ab Utilizacao de cetoconazole e substancias relacionadas em medicamentos para o tratamento da diabetes tipo ii
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure

Also Published As

Publication number Publication date
ATE244009T1 (de) 2003-07-15
CZ36097A3 (en) 1997-06-11
DE69432905T2 (de) 2004-05-27
WO1996004912A1 (en) 1996-02-22
NO314616B1 (no) 2003-04-22
AU7711894A (en) 1996-03-07
PT779810E (pt) 2003-11-28
EP0779810B8 (en) 2003-09-17
ES2202326T3 (es) 2004-04-01
NO970567D0 (no) 1997-02-07
DK0779810T3 (da) 2003-10-20
CZ285290B6 (cs) 1999-06-16
EP0779810B1 (en) 2003-07-02
KR100422162B1 (ko) 2004-07-07
JPH10510241A (ja) 1998-10-06
US5849740A (en) 1998-12-15
KR970704440A (ko) 1997-09-06
JP3825469B2 (ja) 2006-09-27
AU695011B2 (en) 1998-08-06
NO970567L (no) 1997-02-07
CA2196174A1 (en) 1996-02-22
CA2196174C (en) 2005-03-01
EP0779810A1 (en) 1997-06-25
EP1360960A1 (en) 2003-11-12
US6166017A (en) 2000-12-26
DE69432905D1 (de) 2003-08-07

Similar Documents

Publication Publication Date Title
SI0779810T1 (en) Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
ATE186460T1 (de) Methode zur verhinderung von restenosierung nach rekanalisierung von körpergefässen
KR970706002A (ko) 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men)
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
SE9802080D0 (sv) Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
IL131801A0 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
AU2003224742A1 (en) Method of administering buprenorphine to treat depression
MXPA01013384A (es) Metodos para tratar diabetes.
WO2004087076A3 (en) Methods for inhibiting adipogenesis and for treating type 2 diabetes
NO894008L (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
IL130500A (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
Barry et al. The effects of recombinant human growth hormone on cardiopulmonary function in elective abdominal aortic aneurysm repair
MX9707939A (es) Uso de antagonistas del factor inhibidor de la leucemia y la endotelina.
Azizi et al. Long-term cardiac effects of hypotensive agents in normotensive mature rats: comparison of β-blocking agent and converting enzyme inhibition
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
ES8602799A1 (es) Un procedimiento para preparar 6-metilsulfoxido-espiro-(croman-4,4'-imidazolidin)-2',5'-diona
UA32255A (uk) Спосіб лікування цукрового діабету
WO2004064855A8 (de) Medikament und verwendung zur tumortherapie
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
Kaido et al. Temporal profile of gene induction after venous ischemia accompanied by spreading depression as compared to spreading depression alone
郭学梅 Treatment of 42 Cases of Alopecia Areata with Plum-Blossom Needle
RU97106072A (ru) Применение ингибитора ароматазы для получения лекарственного средства при лечении относительного дефицита андрогенов у мужчины
GEP20012487B (en) Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose